Global Anti Obesity Drugs
Market Report
2024
Anti Obesity Drugs Market Report 2024 (Global Edition)
Anti Obesity Drugs market size was $6,616.20 Million in 2024 and it is forecasted to reach $31,199 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be 30.15% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Anti Obesity Drugs Market Report 2024.
Global Anti Obesity Drugs Market Report 2024 Market Size Split by Type (Prescription Drugs, OTC Drugs), by Distributional Channel (Hospital Pharmacy, Retail, Online Pharmacy)
As per Cognitive Market Research's latest published report, the Global Anti Obesity Drugs market size was $6,616.20 Million in 2024 and it is forecasted to reach $31,199 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be 30.15% from 2024 to 2031.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Anti Obesity Drugs Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 30.15% |
| North America Anti Obesity Drugs Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 30.07% |
| Europe Anti Obesity Drugs Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 29.45% |
| Asia Pacific Anti Obesity Drugs Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 31.01% |
| South America Anti Obesity Drugs Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 30.71% |
| Middle East and Africa Anti Obesity Drugs Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 29.17% |
| Market Split by Type |
|
| Market Split by Distributional Channel |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Anti Obesity Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Anti Obesity Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Anti Obesity Drugs Market Report Description
What is Anti Obesity Drug?
An anti-obesity drug, also known as a weight-loss medication, is a pharmaceutical substance specifically designed to help individuals lose weight or manage their weight in cases of obesity or overweight conditions. These medications work through various mechanisms to either suppress appetite, reduce absorption of nutrients, or increase metabolism, thereby aiding in weight reduction. While they can be effective tools in conjunction with lifestyle changes such as diet and exercise, they are typically prescribed for individuals with a body mass index (BMI) of 30 or higher, or 27 or higher with obesity-related conditions like type 2 diabetes or high blood pressure.
One class of anti-obesity drugs includes appetite suppressants. These medications work by targeting neurotransmitters in the brain, such as serotonin and norepinephrine, which regulate feelings of hunger and satiety. By altering these neurotransmitters, appetite suppressants can help reduce food cravings and overall calorie intake. For example, drugs like phentermine and diethylpropion are stimulant medications that can suppress appetite and promote weight loss when combined with a reduced-calorie diet and exercise.
Another class of anti-obesity drugs includes those that interfere with the absorption of nutrients in the gastrointestinal tract. Orlistat is a notable example, which works by inhibiting pancreatic lipase, an enzyme that breaks down fats in the intestine. By blocking the absorption of dietary fats, Orlistat reduces the amount of calories absorbed by the body, thereby aiding in weight loss. However, side effects such as oily stools and flatulence can occur with the use of Orlistat, particularly when dietary fat intake is not reduced.
Market Dynamics of the Anti Obesity Drug Market
Market Drivers of the Anti Obesity Drug Market
- Rising prevalence of obesity significantly boost the anti obesity drug market growth
The rising prevalence of obesity has been a significant driver behind the growth of the anti-obesity drug market. Obesity rates have been steadily rising worldwide over the past few decades, reaching epidemic proportions in many countries. This rise is attributed to a combination of factors, including changes in dietary habits, sedentary lifestyles, urbanization, and socioeconomic factors. As a result, obesity has become a major public health concern, leading to an array of associated health problems such as type 2 diabetes, cardiovascular diseases, and certain types of cancer.
For instance, in 22 October2019, according to the study, nearly one out of every four individuals in OECD countries are obese, a figure that climbs to nearly 60% of the population when including those who are overweight. Despite efforts to address this issue, there has been a notable increase in the number of individuals adopting unhealthy lifestyles, resulting in a continuous rise in obesity rates. Additionally, for instance, in March 2022, an article released by the World Health Organization (WHO) revealed that the global population of individuals classified as obese surpassed 1 billion. Among them, 650 million were adults, 340 million were adolescents, and 39 million were children, all experiencing compromised health as a result of being overweight or obese.
The obesity epidemic has led to a number of negative effects, one of which is an increase in the need for efficient weight-management programs that also enhance general health. Even though diet and activity changes are still the cornerstones of obesity therapy, certain people may not always benefit from them, especially if they have underlying metabolic problems or are extremely obese. Pharmaceutical companies now have a huge window of opportunity to develop and market anti-obesity medications that can supplement conventional therapies.
For example, medications such as liraglutide, an agonist of the glucagon-like peptide-1 (GLP-1) receptor, and orlistat, which slows the absorption of dietary fats, have been licensed for the long-term management of weight in obese individuals or those with overweight and obesity-related comorbidities. These medications have shown promise in enhancing metabolic parameters and encouraging weight loss, making them useful additions to the arsenal of treatments for obesity.
The pharmaceutical sector has also increased its research and development efforts to find new therapeutic targets and create cutting-edge anti-obesity medications as a result of the obesity epidemic. To find viable treatment targets, this entails looking into the processes underpinning energy metabolism, appetite control, and fat storage. Innovation in the field of drug development has been further stimulated by technological advancements like high-throughput screening and computer modeling, which have sped up the identification and optimization of therapeutic candidates.
Additionally, the financial burden of obesity-related medical expenses has encouraged politicians and healthcare systems to fund initiatives that can lessen the negative effects of obesity on public health. This involves providing funds for research, regulatory incentives, and reimbursement policies to assist the development and accessibility of anti-obesity medications. Pharmaceutical companies are attempting to address the growing demand for efficient obesity therapies, which has led to a surge in investment and market expansion in the anti-obesity medicine market.
Thus, the increasing prevalence of obesity has acted as a catalyst for the growth of the anti-obesity drug market by creating a greater demand for effective treatments, fostering innovation in drug development, and attracting investment from stakeholders across the healthcare ecosystem. As the obesity epidemic continues to pose a significant health challenge globally, the market for anti-obesity drugs is expected to expand further, offering new opportunities for therapeutic advancement and improved patient outcomes.
- Increasing chronic diseases is expected to drive the anti obesity drug market growth
The escalating prevalence of chronic diseases is anticipated to be a key driver behind the growth of the anti-obesity drug market. Chronic diseases such as type 2 diabetes, cardiovascular diseases, hypertension, and certain cancers are closely linked to obesity. As obesity rates continue to rise globally, so does the incidence of these debilitating chronic conditions. This creates a pressing need for effective interventions to manage obesity and reduce the risk of associated comorbidities, thereby driving the demand for anti-obesity drugs.
For instance, obesity is a major risk factor for the development of type 2 diabetes, with a significant proportion of diabetic cases attributed to excess body weight. As the diabetic population grows due to increasing obesity rates, there is a parallel increase in the demand for anti-obesity drugs that can help individuals achieve weight loss and improve glycemic control. Drugs such as GLP-1 receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for diabetes management, have also shown efficacy in promoting weight loss, making them valuable in the treatment of obesity and its related complications. For instance, according to National Health Survey nearly half of the population, approximately 12.6 million individuals, experienced at least one chronic condition, with females exhibiting a higher likelihood compared to males (52.3% versus 47.4%).
Covid-19 Impact on Anti Obesity Drug Market
The global anti obesity market was positively impacted by COVID-19. Corona virus disease (COVID-19) which is almost unknown to world before December 2019 declared a Public Health Emergency of International Concern (PHEIC) within three months of its emergence. The variable seriousness of COVID-19 disease is probably going to be multifactorial and age, sex, extreme corpulence and diabetes are settled hazard factors for expanded horribleness and mortality. Separation and restriction of movements (quarantine) for the purpose of preventing transmission of diseases, is associated to the interruption of the work routine and stay in boredom that may be associated with a greater energy intake20. Additionally, this pandemic might be stressful. Stress pushed people towards comfort foods21 and food craving, multidimensional idea including passionate (serious want to eat), social (looking for food), psychological (contemplations about food) and physiological (salivation) forms. COVID-19 patients with extreme stoutness were multiple times bound to require obtrusive mechanical ventilation with a BMI23. Furthermore, metabolic syndrome seems may be related with a worse prognosis in patients of COVID-19. There was an increase in obesity in global population which resulted in increased demand for anti obesity drugs during post-pandemic period.
We have various report editions of Anti Obesity Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape of the Anti Obesity Drug Market
Novo Nordisk A/S
Novo Nordisk A/S is a pharmaceutical company involved in the manufacturing of medicines or drugs for diabetes and obesity care, and rare diseases. The company has a presence in over 170 countries. The company has 10 research and development centers in five countries (China, Denmark, India, the UK, and the US), and 16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Iran, Japan, Russia, and US).
Anti Obesity Drug Industry News
February 2024
Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction
Novo Nordisk announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.
(Source-https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167017)
August 2023
Novo Nordisk strikes $11bn deal to expand production of weight loss drug Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s valuation beyond $500bn.
The group reported record sales for 2023, driven by surging demand for its diabetes and anti-obesity drugs Ozempic and Wegovy. However, Novo Nordisk warned that supply chain bottlenecks were hampering its ability to produce enough of the best-selling treatments.
Top Companies Market Share in Anti Obesity Drugs Industry: (In no particular order of Rank)
- NOVO NORDISK USA
- GSK plc
- Currax Pharmaceuticals LLC
- Others
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional analysis of the Anti Obesity Drug Market
North America accounted for the share of 42.34% in 2023, with CAGR of 30.07% for the forecasted period. In the United States, 1 in 5 children and adolescents and 2 out of 5 adults are obese, while many more are overweight. Type 2 diabetes, heart disease, stroke, and some cancers are just a few of the major health issues that obesity is associated with. The prevalence of obesity in several racial/ethnic groups raises their likelihood of developing chronic illnesses. In addition, The Centers for Disease Control and Prevention estimate that over 40% of Americans are obese, and that percentage has risen by almost 40% in the last 20 years. Individuals who are obese have a higher risk of developing dementia, arthritis, many types of cancer, and cardiovascular disease. Moreover, according to the American Academy of Pediatrics' standards, 14.4 million children and adolescents in the United States suffer from obesity and overweight, which is considered "one of the most common pediatric chronic diseases."
For instance, the therapeutic landscape has changed as a result of a new generation of anti-obesity medications that offer effective new therapies for weight loss but also raise questions about how best to use them and where to put lifestyle-based interventions, which have long had a central position, in relation to them. The medications, known as GLP-1 receptor agonists, were created to treat Type 2 diabetes, whose incidence has increased dramatically in recent years along with obesity trends in the United States. In addition to controlling blood sugar, these drugs cause weight loss, an effect that has drawn attention from the general public and pharmaceutical companies, who have responded by developing customized formulations to aid in weight loss.
The current report Scope analyzes Anti Obesity Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Anti Obesity Drugs Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
North America Anti Obesity Drugs Market
North America Anti Obesity Drugs market Analysis
North America Anti Obesity Drugs market size was $2,799.66 Million in 2024 and it is forecasted to reach $13,150.65 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be 30.07% from 2024 to 2031.
North America accounted for the share of 42.34% in 2023, with CAGR of 30.07% for the forecasted period. In the United States, 1 in 5 children and adolescents and 2 out of 5 adults are obese, while many more are overweight. Type 2 diabetes, heart disease, stroke, and some cancers are just a few of the major health issues that obesity is associated with. The prevalence of obesity in several racial/ethnic groups raises their likelihood of developing chronic illnesses. In addition, The Centers for Disease Control and Prevention estimate that over 40% of Americans are obese, and that percentage has risen by almost 40% in the last 20 years. Individuals who are obese have a higher risk of developing dementia, arthritis, many types of cancer, and cardiovascular disease. Moreover, according to the American Academy of Pediatrics' standards, 14.4 million children and adolescents in the United States suffer from obesity and overweight, which is considered "one of the most common pediatric chronic diseases."
For instance, the therapeutic landscape has changed as a result of a new generation of anti-obesity medications that offer effective new therapies for weight loss but also raise questions about how best to use them and where to put lifestyle-based interventions, which have long had a central position, in relation to them. The medications, known as GLP-1 receptor agonists, were created to treat Type 2 diabetes, whose incidence has increased dramatically in recent years along with obesity trends in the United States. In addition to controlling blood sugar, these drugs cause weight loss, an effect that has drawn attention from the general public and pharmaceutical companies, who have responded by developing customized formulations to aid in weight loss.
Europe Anti Obesity Drugs Market
Europe Anti Obesity Drugs market Analysis
Europe Anti Obesity Drugs market size was $1,671.59 Million in 2024 and it is forecasted to reach $7,631.62 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be 29.45% from 2024 to 2031.
Europe accounted for the share of 25.40% in 2023, with CAGR of 29.45% for the forecasted period. The market for anti-obesity medications in Europe has experienced notable expansion and change in the past few years, which is indicative of the rising incidence of obesity and associated health issues throughout the region. The need for effective pharmaceutical therapies has increased as obesity has become a significant public health issue due to changing food habits, lifestyles, and an increasingly sedentary population. The market is filled with a wide range of medications designed to battle obesity by focusing on several physiological mechanisms such as appetite suppression, obstruction of fat absorption, and metabolic modulation that are involved in weight control.
For instance, NHS statistics shows that obesity costs the health service GBP 6.5 billion year and is one of the main causes of serious illnesses like cancer, diabetes, and cardiovascular disease. Semaglutide (Wegovy) was advised to be used earlier this year by the UK's National Institute for Health and Care Excellence (NICE) for persons with a BMI of at least 35 and one weight-related medical condition, such as diabetes or high blood pressure. In addition, the only drugs regulated and approved for weight loss in the UK at this time are Orlistat, Saxenda, and Wegovy.
Asia Pacific Anti Obesity Drugs Market
Asia Pacific Anti Obesity Drugs market Analysis
Asia Pacific Anti Obesity Drugs market size was $1,317.45 Million in 2024 and it is forecasted to reach $6,463.78 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be 31.01% from 2024 to 2031.
Asia Pacific accounted for the share of 19.78% in 2023, with CAGR of 31.01% for the forecasted period. The Asia Pacific Anti-Obesity drugs market has experienced a significant rise in recent times, which can be attributed to the region's increasing obesity rates and the increasing acceptance of obesity as a significant public health concern. Rapid urbanization, sedentary lifestyles, and changes in eating habits have all contributed to the rise of obesity as a major health issue in many Asia Pacific nations. This has led to a rise in the need for efficient pharmaceutical treatments to address obesity and the risks to health that come with it. The market includes a wide variety of anti-obesity medications that target different aspects of controlling weight, such as enhancing satiety, reducing appetite, and modifying fat metabolism.
For instance, India has about 70 million obese people, hence the market for anti-obesity medications is expanding gradually. According to official data from the National Family Health Survey (NFHS) 2022, one in four Indians is overweight. In 2023, Indian pharmaceutical companies are developing anti-obesity drugs more quickly due to increased demand and an increase in Ozempic sales. Given the growing potential in the domestic market, Indian pharmaceutical companies are racing to produce weight loss drugs in anticipation of an increase in sales of Novo Nordisk's popular diabetic and weight reduction drug Ozempic (semaglutide).
South America Anti Obesity Drugs Market
South America Anti Obesity Drugs market Analysis
South America Anti Obesity Drugs market size was $678.44 Million in 2024 and it is forecasted to reach $3,282.01 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be 30.71% from 2024 to 2031.
South America accounted for the share of 10.21% in 2023, with CAGR of 30.71% for the forecasted period. The market for anti-obesity drugs in South America has grown significantly in recent years due to a number of causes, such as rising obesity rates, increased public awareness of health and wellness, and improvements in pharmaceutical research and development. The prevalence of obesity has increased due to sedentary lifestyles, shifting eating choices, and urbanization, and it has become a major public health concern throughout the region. Consequently, there has been an increase in the need for efficient therapies to tackle obesity and the related health hazards. For instance, Trials have demonstrated the well-established efficacy of most medications approved in Brazil for the pharmacotherapy of obesity in weight loss. Orlistat, liraglutide, and lorcaserin all showed comparable rates of adverse events; liraglutide, however, had the highest number of gastrointestinal problems among the group.
In addition, South America has anti-obesity drugs. A sympathomimetic phenylethylamine is phentermine. Its anorexic impact results from a rise in noradrenaline release in the central nervous system, with smaller releases of dopamine and serotonin.
South America's anti-obesity drug industry is characterized by a wide variety of pharmaceutical goods, such as over-the-counter, prescription, and herbal supplements. Pharmaceutical companies are actively involved in the development of new drugs and the optimization of current formulations to target the intricate physiological processes that cause obesity. In an effort to promote weight loss and enhance metabolic health, these medications often function by decreasing nutrient absorption, suppressing hunger, or speeding up metabolism.
Middle East and Africa Anti Obesity Drugs Market
Middle East and Africa Anti Obesity Drugs market Analysis
Middle East and Africa Anti Obesity Drugs market size was $149.06 Million in 2024 and it is forecasted to reach $671.67 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be 29.17% from 2024 to 2031.
Middle East and Africa accounted for the share of 2.27% in 2023, with CAGR of 29.17% for the forecasted period. The anti-obesity drug market in the Middle East and Africa (MEA) is a dynamic, ever-changing environment that is affected by a number of intricate relationships between socioeconomic, healthcare, and demographic factors. A major public health concern in the region, obesity is on the rise due to sedentary lifestyles, fast urbanization, and shifting food preferences. Consequently, there is a rising need for practical ways to combat obesity and the health risks it entails, including diabetes, heart disease, and several types of cancer.
For instance, In the UAE, teriposide is marketed as Mounjaro, while semaglutide, under the brand name Wegovy, is registered for weight loss instead of Ozempic, which is registered for Type 2 diabetes. It is recommended as a therapy for obesity and diabetes.
The oil-rich region is experiencing a surge in popularity for Ozempic, as obesity rates are among the highest globally. This can be attributed to factors such as the almost universal availability of cars, intense heat that forces people indoors, and the growing popularity of processed foods. According to the Global Nutrition Report, approximately 31% of men and 44% of women in the United Arab Emirates and approximately 46% of women in Qatar are obese, respectively.
Anti Obesity Drugs Market Analysis
Global Anti Obesity Drugs Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Anti Obesity Drugs Industry growth. Anti Obesity Drugs market has been segmented with the help of its Type, Distributional Channel , and others. Anti Obesity Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Type Segment Analysis of Anti Obesity Drugs Market
Based on present and future trends, the market size is estimated from 2019 to 2031. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Anti Obesity Drugs market.
Type of Anti Obesity Drugs analyzed in this report are as follows:
- Prescription Drugs
- OTC Drugs
Anti Obesity Drugs Market Share (%) by Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Anti Obesity Drugs Industry. Request a Free Sample PDF!
Distributional Channel Segment Analysis of Anti Obesity Drugs Market
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Anti Obesity Drugs from 2019 to 2031. This will also help to analyze the demand for Anti Obesity Drugs across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.
Some of the key Distributional Channel of Anti Obesity Drugs are:
- Hospital Pharmacy
- Retail
- Online Pharmacy
Anti Obesity Drugs Market Share (%) by Distributional Channel in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Author's Detail
Anushka GoreResearch Associate at Cognitive Market Research
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical devices & consumables industry. She has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations.
In her current role, Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses. Her collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization.Anushka remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Anti Obesity Drugs Market is witnessing significant growth in the near future.
In 2023, the Prescription Drugs segment accounted for noticeable share of global Anti Obesity Drugs Market and is projected to experience significant growth in the near future.
The Hospital Pharmacy segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies NOVO NORDISK USA , Currax Pharmaceuticals LLC and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Anti Obesity Drugs Market
Sources from Medical Devices & Consumables Industry
- http://www.trade.gov
- http://www.gov.uk
- http://www.fda.gov
- http://www.hhs.gov
- http://www.who.int
- http://www.bls.gov
- http://www.gao.gov
- http://www.ncbi.nlm.nih.gov
- http://www.healthcaredive.com
- http://www.weforum.org
- http://www.health.gov.za
- http://www.usaid.gov
- http://www.eumdr.com
- http://www.cdc.gov
- http://www.ama-assn.org
- http://www.washingtonpost.com
- http://www.ecfr.gov
- http://www.hbr.org
- http://www.worldbank.org
- http://www.commission.europa.eu
- http://www.cbi.eu
- http://www.unicef.org
- http://www.ecipe.org
- http://www.ema.europa.eu
Anti Obesity Drugs Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Type | Prescription Drugs, OTC Drugs |
| Distributional Channel | Hospital Pharmacy, Retail, Online Pharmacy |
| List of Competitors | NOVO NORDISK USA, GSK plc, Currax Pharmaceuticals LLC, Others |
This chapter will help you gain GLOBAL Market Analysis of Anti Obesity Drugs. Further deep in this chapter, you will be able to review Global Anti Obesity Drugs Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Anti Obesity Drugs Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Anti Obesity Drugs Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Anti Obesity Drugs Revenue Market Size By Region
-
-
1.3 Global Anti Obesity Drugs Market Size By Type 2019 -2031
-
1.3.1 Prescription Drugs Market Size
-
1.3.2 OTC Drugs Market Size
-
-
1.4 Global Anti Obesity Drugs Market Size By Distributional Channel 2019 -2031
-
1.4.1 Hospital Pharmacy Market Size
-
1.4.2 Retail Market Size
-
1.4.3 Online Pharmacy Market Size
-
-
1.5 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.6 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.6.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.6.2 Global Market Revenue Split By Type
-
1.6.3 Global Market Revenue Split By Distributional Channel
-
1.6.4 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Anti Obesity Drugs Market Size 2019 - 2031
-
2.1.1 North America Anti Obesity Drugs Market Size By Country 2019 - 2031
-
2.1.2 North America Anti Obesity Drugs Market Size by Type 2019 -2031
-
2.1.2.1 North America Prescription Drugs Market Size
-
2.1.2.2 North America OTC Drugs Market Size
-
-
2.1.3 North America Anti Obesity Drugs Market Size by Distributional Channel 2019 -2031
-
2.1.3.1 North America Hospital Pharmacy Market Size
-
2.1.3.2 North America Retail Market Size
-
2.1.3.3 North America Online Pharmacy Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Anti Obesity Drugs Market Size 2019 - 2031
-
3.1.1 Europe Anti Obesity Drugs Market Size By Country 2019 - 2031
-
3.1.2 Europe Anti Obesity Drugs Market Size by Type 2019 -2031
-
3.1.2.1 Europe Prescription Drugs Market Size
-
3.1.2.2 Europe OTC Drugs Market Size
-
-
3.1.3 Europe Anti Obesity Drugs Market Size by Distributional Channel 2019 -2031
-
3.1.3.1 Europe Hospital Pharmacy Market Size
-
3.1.3.2 Europe Retail Market Size
-
3.1.3.3 Europe Online Pharmacy Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Anti Obesity Drugs Market Size 2019 - 2031
-
4.1.1 Asia Pacific Anti Obesity Drugs Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Anti Obesity Drugs Market Size by Type 2019 -2031
-
4.1.2.1 Asia Pacific Prescription Drugs Market Size
-
4.1.2.2 Asia Pacific OTC Drugs Market Size
-
-
4.1.3 Asia Pacific Anti Obesity Drugs Market Size by Distributional Channel 2019 -2031
-
4.1.3.1 Asia Pacific Hospital Pharmacy Market Size
-
4.1.3.2 Asia Pacific Retail Market Size
-
4.1.3.3 Asia Pacific Online Pharmacy Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Anti Obesity Drugs Market Size 2019 - 2031
-
5.1.1 South America Anti Obesity Drugs Market Size By Country 2019 - 2031
-
5.1.2 South America Anti Obesity Drugs Market Size by Type 2019 -2031
-
5.1.2.1 South America Prescription Drugs Market Size
-
5.1.2.2 South America OTC Drugs Market Size
-
-
5.1.3 South America Anti Obesity Drugs Market Size by Distributional Channel 2019 -2031
-
5.1.3.1 South America Hospital Pharmacy Market Size
-
5.1.3.2 South America Retail Market Size
-
5.1.3.3 South America Online Pharmacy Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Anti Obesity Drugs Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Anti Obesity Drugs Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Anti Obesity Drugs Market Size by Type 2019 -2031
-
6.1.2.1 Middle East and Africa Prescription Drugs Market Size
-
6.1.2.2 Middle East and Africa OTC Drugs Market Size
-
-
6.1.3 Middle East and Africa Anti Obesity Drugs Market Size by Distributional Channel 2019 -2031
-
6.1.3.1 middle_east_and_africa_title} Hospital Pharmacy Market Size
-
6.1.3.2 middle_east_and_africa_title} Retail Market Size
-
6.1.3.3 middle_east_and_africa_title} Online Pharmacy Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Anti Obesity Drugs Market Size by Type 2019 -2031
-
7.1.2 Country 1Anti Obesity Drugs Market Size by Distributional Channel 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Anti Obesity Drugs Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 NOVO NORDISK USA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 GSK plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Currax Pharmaceuticals LLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Others
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
-
10.1 Prescription Drugs
-
10.1.1 Global Anti Obesity Drugs Revenue Market Size and Share by Prescription Drugs 2019 -2031
-
-
10.2 OTC Drugs
-
10.2.1 Global Anti Obesity Drugs Revenue Market Size and Share by OTC Drugs 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Distributional Channel Analysis 2019 -2031
-
11.1 Hospital Pharmacy
-
11.1.1 Global Anti Obesity Drugs Revenue Market Size and Share by Hospital Pharmacy 2019 - 2031
-
-
11.2 Retail
-
11.2.1 Global Anti Obesity Drugs Revenue Market Size and Share by Retail 2019 - 2031
-
-
11.3 Online Pharmacy
-
11.3.1 Global Anti Obesity Drugs Revenue Market Size and Share by Online Pharmacy 2019 - 2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Anti Obesity Drugs market
Chapter 12 Research Findings
-
12.1 Key Takeaways
-
12.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
12.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Anushka Gore and Team
- 1.1 Anti Obesity Drugs Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Anti Obesity Drugs Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Anti Obesity Drugs Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Anti Obesity Drugs Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Anti Obesity Drugs Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Anti Obesity Drugs Market
Key Questions Answered By Anti Obesity Drugs Market Report 2024
| Why Prescription Drugs have a significant impact on Anti Obesity Drugs market? |
| What are the key factors affecting the Prescription Drugs and OTC Drugs of Anti Obesity Drugs Market? |
| What is the CAGR/Growth Rate of Hospital Pharmacy during the forecast period? |
| By type, which segment accounted for largest share of the global Anti Obesity Drugs Market? |
| Which region is expected to dominate the global Anti Obesity Drugs Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
